These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23085742)

  • 1. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):81-5. PubMed ID: 24486167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Niwa S; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S; Watanabe A; Ikematsu H; Uemori M; Awamura S;
    Clin Infect Dis; 2016 Aug; 63(3):330-7. PubMed ID: 27118785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M; Matsumoto T; Fujii T
    Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
    Nakano T; Yamaguchi H; Chiba T; Shiosakai K; Chikada S; Matsuoka Y
    J Infect Chemother; 2021 Oct; 27(10):1436-1446. PubMed ID: 34226112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M
    Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single inhalation of laninamivir octanoate in children with influenza.
    Katsumi Y; Otabe O; Matsui F; Kidowaki S; Mibayashi A; Tsuma Y; Ito H
    Pediatrics; 2012 Jun; 129(6):e1431-6. PubMed ID: 22614774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
    J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons.
    Tani N; Kawai N; Ikematsu H; Bando T; Iwaki N; Takasaki Y; Shindo S; Chong Y; Kashiwagi S
    J Infect Chemother; 2022 Jul; 28(7):890-895. PubMed ID: 35317975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
    Watanabe A
    J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.